DR. KAVITHA PANDY RAJ, MD
Osteopathic Medicine at Las Positas Blvd, Pleasanton, CA
License number
California A93219
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
5725 W Las Positas Blvd SUITE 100, Pleasanton, CA 94588
Phone
(925) 734-8130
Personal information
See more information about KAVITHA PANDY RAJ at radaris.comName
Address
Phone
772 Pradera Way, San Ramon, CA 94583
Professional information
See more information about KAVITHA PANDY RAJ at trustoria.com
Dr. Kavitha P Raj, Pleasanton CA - MD (Doctor of Medicine)
Dr. Kavitha P Raj, Pleasanton CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
5725 W Las Positas Blvd, Pleasanton 94588
(925) 734-8130 (Phone)
Valley Medical Oncology Consultants
5725 W Las Positas Blvd SUITE 100, Pleasanton 94588
(925) 734-8130 (Phone)
(925) 734-8130 (Phone)
Valley Medical Oncology Consultants
5725 W Las Positas Blvd SUITE 100, Pleasanton 94588
(925) 734-8130 (Phone)
Languages:
English
Hospitals:
5725 W Las Positas Blvd, Pleasanton 94588
Valley Medical Oncology Consultants
5725 W Las Positas Blvd SUITE 100, Pleasanton 94588
San Ramon Regional Medical Center
6001 Norris Canyon Rd, San Ramon 94583
Valley Medical Oncology Consultants
5725 W Las Positas Blvd SUITE 100, Pleasanton 94588
San Ramon Regional Medical Center
6001 Norris Canyon Rd, San Ramon 94583
Philosophy:
Our team of highly skilled physicians and nurses are dedicated to providing comprehensive and compassionate Hematology/Oncology care in several modern state-of-the art facilities. We take great pride in our patient centered care philosophy; at our clinics "the patient always comes first."
Education:
Residency Hospital
University Of Nv School Of Med
University Of Nv School Of Med
Kavitha Pandy Raj, Pleasanton CA
Kavitha Pandy Raj, Pleasanton CA
Specialties:
Internist
Address:
5725 W Las Positas Blvd, Pleasanton, CA 94588
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Hospice and Palliative Medicine (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Kavitha P Raj, Pleasanton CA
Kavitha P Raj, Pleasanton CA
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology, Hospitalist
Work:
Valley Medical Oncology
5725 W Las Psts Blvd, Pleasanton, CA 94588 Valley Medical Oncology
5601 Norris Canyon Rd, San Ramon, CA 94583 Uci Medical Center
101 The City Dr S, Orange, CA 92868
5725 W Las Psts Blvd, Pleasanton, CA 94588 Valley Medical Oncology
5601 Norris Canyon Rd, San Ramon, CA 94583 Uci Medical Center
101 The City Dr S, Orange, CA 92868
Education:
Kilpauk Medical College (1999)
Cancer Prevention And Treatment Methods Based On Dietary Polyamine Content
Cancer Prevention And Treatment Methods Based On Dietary Polyamine Content
US Patent:
2013021, Aug 22, 2013
Filed:
May 13, 2011
Appl. No.:
13/697984
Inventors:
Kavitha P. Raj - Pleasanton CA, US
Jason A. Zell - Dana Point CA, US
Christine E. Mclaren - Irvine CA, US
Eugene W. Gerner - Tucson AZ, US
Jeffrey Jacob - Tucson AZ, US
Jason A. Zell - Dana Point CA, US
Christine E. Mclaren - Irvine CA, US
Eugene W. Gerner - Tucson AZ, US
Jeffrey Jacob - Tucson AZ, US
Assignee:
CANCER PREVENTION PHARMACEUTICALS, INC. - Tucson AZ
CANCER PREVENTION PHARMACEUTICAL, INC - Tucson AZ
THE REGENT OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION - Oakland CA
CANCER PREVENTION PHARMACEUTICAL, INC - Tucson AZ
THE REGENT OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION - Oakland CA
International Classification:
A61K 31/198, A61K 31/415, A61K 31/192
US Classification:
514406, 514564
Abstract:
Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N-acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.